|2.||Peptic Ulcer (Peptic Ulcers)
|3.||Stomach Ulcer (Gastric Ulcer)
|4.||Duodenal Ulcer (Curling's Ulcer)
|1.||Jensen, Robert T: 8 articles (02/2013 - 02/2002)|
|2.||Hirschowitz, Basil I: 6 articles (06/2011 - 05/2002)|
|3.||Metz, D C: 6 articles (02/2006 - 01/2000)|
|4.||Jensen, R T: 6 articles (04/2002 - 05/2000)|
|5.||Metz, David C: 5 articles (08/2013 - 02/2003)|
|6.||Pisegna, Joseph R: 5 articles (12/2007 - 06/2002)|
|7.||Poitras, Pierre: 4 articles (08/2013 - 05/2011)|
|8.||Rehfeld, Jens F: 4 articles (08/2013 - 05/2011)|
|9.||Bartsch, Detlef K: 4 articles (12/2011 - 12/2005)|
|10.||Fendrich, Volker: 4 articles (12/2011 - 12/2005)|
|1.||Omeprazole (Esomeprazole)FDA LinkGeneric
01/01/1989 - "Omeprazole has been found to be very effective in the Zollinger-Ellison syndrome, with a prompt effect on acid secretion and symptoms. "
01/01/2008 - "Esomeprazole also effectively treated patients with Zollinger-Ellison syndrome. "
11/01/1992 - "The efficacy of omeprazole increases during the first few days of administration, suggesting that long-term maintenance dose requirements in patients with Zollinger-Ellison syndrome may be lower than those initially established by upward titration. "
04/01/1993 - "Periodic clinical and endoscopic assessments, and measurement of basal acid secretion showed the efficacy of this low dose of omeprazole in our Zollinger-Ellison syndrome patients. "
04/01/1993 - "Efficacy of long-term therapy with low doses of omeprazole in the control of gastric acid secretion in Zollinger-Ellison syndrome patients."
|2.||lansoprazole (Prevacid)FDA LinkGeneric
11/01/2001 - "When individually optimized, lansoprazole proved to be safe and effective in the control of secretion for the treatment of both Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome hypersecretors for up to 10 years."
08/01/1996 - "Lansoprazole is apparently safe and effective for treating hypersecretion, whether due to hypergastrinaemia (Zollinger-Ellison syndrome) or not (non-Zollinger-Ellison syndrome hypersecretors)."
01/01/1993 - "These results demonstrate that long-term treatment with lansoprazole is both safe and effective in patients with Zollinger-Ellison syndrome, and suggest that this drug will be useful in such patients. "
06/01/2011 - "Over a 20-year period, patients with Zollinger-Ellison syndrome were enrolled in a prospective trial evaluating the efficacy of lansoprazole. "
01/01/1993 - "The long-term safety and efficacy of lansoprazole were studied in 21 patients with Zollinger-Ellison syndrome. "
03/01/1996 - "Zollinger-Ellison syndrome (ZES) is associated with marked plasma elevation of all forms of gastrin and, because of its prolonged course, has been shown to be an excellent model disease to study the effects of chronic hypergastrinemia in man. "
10/01/1977 - "An individual study of the patients with high (up to 300 pg/ml) basal and stimulated serum gastrin levels showed that most gastroduodenal diseases are situated within this range while levels of 500 pg/ml suggest Zollinger-Ellison syndrome. "
05/01/2011 - "The Zollinger-Ellison syndrome and mismeasurement of gastrin."
10/01/2010 - "It was originally an abnormal secretion of gastrin fits the syndrome Zollinger-Ellison. "
08/01/2007 - "Zollinger Ellison syndrome (ZES), an ulcerative disease of the upper gastrointestinal tract that involves the production of high levels of gastrin and gastric acid, is a rare, symptomatic, endocrine neoplastic disease. "
|4.||pantoprazole (Protonix)FDA LinkGeneric
02/01/2006 - "Three-year oral pantoprazole administration is effective for patients with Zollinger-Ellison syndrome and other hypersecretory conditions."
02/01/2003 - "Maintenance oral pantoprazole therapy is effective for patients with Zollinger-Ellison syndrome and idiopathic hypersecretion."
02/01/2006 - "The safety and efficacy data for short-term (6-month) treatment of Zollinger-Ellison syndrome and idiopathic hypersecretion with oral pantoprazole were previously published. "
02/01/2003 - "pantoprazole therapy at a dose of 80-240 mg/day in divided doses was both effective and generally well tolerated for patients with Zollinger-Ellison syndrome and idiopathic hypersecretion."
01/01/2003 - "Oral or intravenous pantoprazole up to 240 mg/day maintained target acid output levels in most patients with hypersecretory conditions, including Zollinger-Ellison syndrome. "
01/01/2010 - "Diagnostic efficacy of the secretin stimulation test for the Zollinger-Ellison syndrome: an intra-individual comparison using different dosages in patients and controls."
05/01/2001 - "In the current study we compared secretin testing results in six confirmed Zollinger-Ellison Syndrome patients using the biologically-derived product and both synthetic products (human and porcine) in a three-way, randomized, single-blind Latin-squares crossover study. "
11/01/2000 - "In this study we report that the intraoperative secretin test (IOS test) is also useful for determining the extent of curability in patients with Zollinger-Ellison syndrome (ZES). "
02/01/1985 - "[A study of secretin dosage of secretin provocation test in the Zollinger-Ellison syndrome]."
08/01/2013 - "Secretin stimulation testing (SST) is used to evaluate patients with hypergastrinemia in the diagnosis of Zollinger-Ellison syndrome. "
|6.||Ranitidine (Zantac)FDA LinkGeneric
08/01/1995 - "These results indicate that, as in Zollinger-Ellison syndrome, ranitidine is effective therapy for patients with idiopathic gastric acid hypersecretion; however, markedly increased doses as large as 3000 mg/day may be required."
10/01/1993 - "These results demonstrate that the parenteral dose of ranitidine required to control acid secretion in patients with Zollinger-Ellison syndrome can be predicted from the oral dose.(ABSTRACT TRUNCATED AT 250 WORDS)"
01/01/1991 - "Ranitidine given as a 50-mg intravenous bolus, followed by a continuous infusion of 0.5 mg.kg/h, controls acid hypersecretion acutely in patients with Zollinger-Ellison syndrome. "
03/01/1986 - "[Zollinger-Ellison syndrome: long-term treatment with ranitidine]."
08/01/1983 - "Ranitidine may prove to be the drug of choice in the medical management of patients with the Zollinger-Ellison syndrome."
|7.||Histamine (Histamine Dihydrochloride)FDA Link
07/01/1987 - "Although most patients with Zollinger-Ellison syndrome can be effectively treated with histamine H2-receptor antagonists, many patients require large doses of drug to inhibit gastric acid secretion adequately. "
10/01/1993 - "In the present study, in 31 patients with Zollinger-Ellison syndrome we evaluated the hypothesis that an effective parenteral histamine H2-receptor antagonist dose could be predicted from the previous oral dose. "
12/01/1998 - "This is caused by an increase in histamine released by the enterochromaffin-like cell secondarily to hypergastrinemia, corresponding to the tolerance towards H2RAs seen in patients with Zollinger-Ellison syndrome."
04/01/1990 - "The highest rates of histamine formation were present in the oxyntic mucosa of patients with Zollinger-Ellison syndrome. "
01/01/1983 - "Failure of histamine H2-receptor antagonist therapy in Zollinger-Ellison syndrome."
|8.||Famotidine (Pepcid)FDA LinkGeneric
07/01/1984 - "[A case of refractory chronic Zollinger-Ellison syndrome--treated successfully with famotidine]."
01/01/1987 - "Famotidine: effective treatment of Zollinger-Ellison syndrome."
10/01/1989 - "In patients with Zollinger-Ellison syndrome, the potency and long duration of action of famotidine may confer an advantage over other H2-receptor antagonists--in individualised doses (mean 0.33 g/day) famotidine successfully controlled acid secretion for up to 72 months in 1 study of such patients. "
02/01/1989 - "Consequently, famotidine might be a suitable drug with long-lasting actions in the treatment of Zollinger-Ellison syndrome. "
04/01/1988 - "Because of its increased antisecretory potency and lack of antiandrogenic effects at higher doses, famotidine may be the H2-receptor antagonist of choice in treating Zollinger-Ellison syndrome. "
|9.||Cimetidine (Biomet)FDA LinkGeneric
05/20/1978 - "In the Zollinger-Ellison syndrome, good results have been obtained but cimetidine treatment must be decided and supervised only by well-informed specialists. "
06/01/1989 - "This study demonstrates that a continuous i.v. infusion of cimetidine adequately inhibits gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. "
07/01/1987 - "Thus 7 of the 9 patients with Zollinger-Ellison syndrome who required more than 2.4 g/day of cimetidine to inhibit gastric acid secretion had abnormal cimetidine pharmacokinetics."
07/01/1987 - "The concentration of cimetidine in the blood required to inhibit gastric acid secretion by 50% was markedly increased in 3 of the patients with Zollinger-Ellison syndrome, suggesting parietal cell resistance. "
07/01/1987 - "Poor responsiveness to cimetidine in patients with Zollinger-Ellison syndrome has several different causes. "
|10.||Somatostatin Receptors (Somatostatin Receptor)IBA
10/01/1999 - "The aim of this paper is to review five recent studies performed at the National Institutes of Health in patients with Zollinger-Ellison syndrome to define the role of somatostatin receptor scintigraphy. "
01/01/1999 - "We review the literature regarding the sensitivity of somatostatin receptor scintigraphy and endoscopic ultrasound and discuss the approach to imaging in Zollinger-Ellison syndrome."
08/01/1998 - "Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome."
07/01/1997 - "Usefulness of somatostatin receptor scintigraphy in the management of patients with Zollinger-Ellison syndrome. "
05/01/1997 - "Somatostatin receptor scintigraphy in the Zollinger-Ellison syndrome."
05/01/1983 - "When the Zollinger-Ellison syndrome was first identified, total gastrectomy was proposed as the most effective treatment for the secretory manifestations of the syndrome. "
05/01/2007 - "Is total gastrectomy still a viable option in the management of patients with the Zollinger-Ellison syndrome?"
02/01/1999 - "We present a 57-year-old man with Zollinger-Ellison syndrome who had undergone total gastrectomy 12 years previously. "
04/01/1992 - "Total gastrectomy in Zollinger Ellison syndrome: does it have no role today?"
01/01/1986 - "Is total gastrectomy still acceptable in the treatment of the Zollinger-Ellison syndrome?"
01/01/2001 - "Eugastrinaemia in Zollinger-Ellison syndrome can be an elusive goal, nearly one third of laparotomies failing to detect the tumour. "
05/01/1987 - "From 1971-1986, 24 patients were diagnosed as having Zollinger-Ellison syndrome (ZES) and 22 patients had laparotomy. "
06/01/1996 - "Laparotomy and proximal gastric vagotomy in Zollinger-Ellison syndrome: results of a 16-year prospective study."
08/01/1985 - "Treatment of Zollinger-Ellison syndrome with exploratory laparotomy, proximal gastric vagotomy, and H2-receptor antagonists. "
12/01/1988 - "Fifty-five consecutive patients with Zollinger-Ellison syndrome who underwent exploratory laparotomies for gastrinoma resection were evaluated prospectively to determine the effect of gastrinoma resection on acid secretion and to establish criteria for safe and effective perioperative management of gastric acid hypersecretion. "
04/01/1994 - "Our treatment suggested the efficacy of chemical adrenalectomy in managing ectopic ACTH syndrome associated with Zollinger-Ellison syndrome."
04/01/1994 - "A case of ectopic ACTH syndrome associated with Zollinger-Ellison syndrome: long-term survival with chemical adrenalectomy."
06/01/1979 - "Cushing's syndrome preceded the appearance of the overt Zollinger-Ellison syndrome by 2 years and was treated by bilateral adrenalectomy. "
06/15/1987 - "Recrudescence of the Cushings and Zollinger-Ellison syndrome was managed by surgical extirpation of the primary tumor and regional metastases as well as bilateral adrenalectomy. "
12/01/1987 - "Effect of parathyroidectomy in patients with hyperparathyroidism, Zollinger-Ellison syndrome, and multiple endocrine neoplasia type I: a prospective study."
03/01/1989 - "A prospective study involving 7 patients with primary hyperparathyroidism and hypergastrinaemia was conducted to assess the time-dependent change in serum gastrin value before and after parathyroidectomy and to determine at which postoperative stage persistent hypergastrinaemia may be indicative of an associated gastrinoma (Zollinger-Ellison syndrome). "
12/01/1987 - "This study evaluates prospectively the effect of parathyroidectomy on basal acid output (BAO), maximal acid output (MAO), fasting serum gastrin, secretin-stimulated serum gastrin, and sensitivity to antisecretory medication in 10 consecutive patients with primary hyperparathyroidism (PHP), Zollinger-Ellison syndrome (ZES), and multiple endocrine neoplasia type I (MEN-I). "